Pibrentasvir

Pibrentasvir (CAS No.: 1353900-92-1) is a novel pan-genotypic hepatitis C virus (HCV) NS5A inhibitor, exhibiting potent inhibitory activity against the NS5A protein of HCV genotypes 1 to 6, with an in vitro half-maximal effective concentration (EC??) range of 1.4 to 5.0 picomolar (pM). In cell-based models, Pibrentasvir interferes with HCV RNA replication and virion assembly by inhibiting the NS5A protein, demonstrating strong antiviral activity. Its use in animal models and drug screening studies is typically determined by the experimental design and research objectives, and the selection of dose or concentration depends on specific experimental conditions and goals.